The Problem: Budget Season Is Here, and Most AI Money Is About to Be Wasted Again
If you're a technology leader at a large pharmaceutical company, chances are you're sitting in budget planning meetings right now. And chances are, someone in the room is about to propose the same mistake the industry made last cycle: spreading AI investment thinly across dozens of pilots, hoping a few stick.
The data says this approach isn't working. Only 22% say they have successfully scaled AI beyond pilot stage, according to Deloitte's 2026 Life Sciences Outlook, based on a survey of 280 C-suite executives across biopharma and medtech in the US, Europe, and Asia. That gap between enthusiasm and execution is exactly where budget gets wasted - funding experimentation without funding the conditions that let experiments scale.
The governance gap compounds the problem. Only 15% of surveyed life sciences and health care executives said their organizations have adapted governance to keep pace with AI, and nearly half report their boards lack representation in AI and data science. Meanwhile, ZS's October 2025 CDIO Outlook survey of 115 pharma and biotech technology executives found that 68% say neglecting data quality and governance early is the primary reason AI initiatives fail. Budgets that skip the unglamorous foundation work are budgets built to underperform.
The Solution: Stop Funding Pilots, Start Funding a Portfolio
The pharma organizations pulling ahead aren't the ones running the most AI experiments - they're the ones running fewer, better-funded, more rigorously measured ones. ZS's research captured this directly: one CDIO described moving past the experimentation phase to concentrate on five to 10 high-impact use cases, each with the potential to deliver 20%-30% ROI, rather than spreading budget across a long tail of speculative pilots.
This concentration is showing up in the numbers. McKinsey's analysis of pharma and medtech gen AI spending found the share of life sciences companies spending $5 million or more on gen AI is projected to grow from 20% in 2024 to 32% in 2025, while the share spending under $5 million is shrinking. Budgets are consolidating around fewer, bigger bets - not more, smaller ones.
At the R&D-technology-budget level specifically, Benchling's November 2025 survey of roughly 100 biotech and pharma organizations found real momentum: 55% of respondents devote 11% or more of their R&D tech budget to AI, distributed across bands of 11–20% (28% of respondents), 21–35% (18%), and above 35% (6%). Budget authority is shifting from "innovation fund" territory into core operating spend.
The Approach: A Data-Grounded Framework for Splitting Your AI Budget
Based on where the research shows measurable value is already being realized - and where it consistently is not - here is the allocation framework we recommend pharma technology leaders bring into this budget cycle:
30% - Data Foundation & Governance. This is the least exciting line item and the one most likely to get cut under pressure - which is precisely why it should be protected first. With 68% of CDIOs citing data quality and governance gaps as the top reason AI initiatives fail, and only 15% of life sciences organizations reporting governance that has kept pace with AI, this allocation buys the master data management, model validation infrastructure, and EU AI Act / Swiss nDSG-aligned governance frameworks that everything else depends on.
40% - Concentrated High-ROI Use Cases (5-10 max). Direct this toward the domains where ZS's survey shows measurable value is already provable: enterprise tech and data operations (49% of respondents already demonstrating consistent value) and commercial functions like HCP engagement and personalization (47%). Resist the temptation to fund a broader portfolio of "interesting" pilots - the CDIOs seeing 20-30% ROI are the ones who said no to the long tail.
20% - Agentic Workflow Automation. This is where 2027 budgets should differ meaningfully from 2026 budgets. ZS's data shows 45% of enterprise IT leaders and 41% of R&D discovery leaders now plan to build end-to-end agentic workflows in the next year, while in commercial functions, 36% plan full workflow transformation and 46% are automating specific high-friction activities. This is no longer an experimental category - it's where the next efficiency wave is coming from, and it requires dedicated budget separate from general AI experimentation.
10% - Compliance Engineering & Cloud Architecture Reserve. Industry analysis from IDC notes that pharma CIOs increasingly need to budget not just for AI R&D itself, but for the compliance engineers and cloud architects who make "closed-loop governed AI" possible in a GxP environment. This reserve line funds the specialized talent and infrastructure that turns a working pilot into an inspection-ready production system - the step where most pharma AI programs currently stall.
The organizations moving fastest aren't necessarily spending the most - they're spending with the most discipline. A concentrated bet on 5-10 use cases, backed by real governance, beats 50 pilots that never leave the sandbox.
What This Looks Like in Practice
Consider how this framework plays out for a mid-size Swiss or EU pharma organization setting its 2027 IT budget. Rather than approving 30 separate departmental AI requests, the CIO consolidates them into a single portfolio view: which 5-10 use cases have executive sponsorship, a named business owner, and a pre-agreed ROI target? Those get the 40% concentrated allocation. Everything else either gets killed, deferred, or folded into the foundation-and-governance line as a shared capability rather than a standalone project.
This is also where budget conversations with the CFO get easier, not harder. A five-line budget built around foundation, concentrated bets, agentic automation, and compliance infrastructure is a business case a board can evaluate. A spreadsheet of 40 departmental pilot requests is not.
How ANG Associates Can Help
ANG Associates helps pharma CIOs and CDIOs translate exactly this kind of framework into an executable, board-ready budget. We bring the combination this task requires: AI strategy expertise to help you identify which 5-10 use cases genuinely merit concentrated investment, deep Life Sciences regulatory knowledge to size the governance and compliance allocation correctly for EU AI Act and Swiss nDSG requirements, and proven IT delivery management to ensure the budget you approve is the budget that actually gets executed - with quality gates, vendor governance, and measurable milestones built in from day one. If you're heading into budget season without a clear, defensible allocation framework, we can help you build one before the numbers are due.
Sources
- Deloitte, "2026 Life Sciences Executive Outlook" (survey of 280 C-suite executives, US/Europe/Asia, Aug-Sept 2025)
- Deloitte, "Life Sciences and Health Care Industry Insights Report 2026"
- ZS, "Scaling AI in Pharma and Biotech: 2026 CDIO Research" (Harris Poll survey of 115 pharma/biotech technology executives, October 2025)
- McKinsey & Company, "AI budgets grow in life sciences"
- Benchling biotech/pharma AI budget survey (~100 organizations, November 2025), via IntuitionLabs, "Biotech AI Budget Benchmarks 2026"
- IDC analysis of pharma CIO AI infrastructure budgeting, via IntuitionLabs, "Pharma AI Infrastructure: 2026 Deals and Investments"